New HIV vaccine trial combines nanoparticles and mRNA to train the immune system
NCT ID NCT05903339
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This early-stage study tests a new HIV vaccine in 36 healthy adults without HIV. The vaccine uses a two-step approach: first, a nanoparticle that displays HIV-like proteins, followed by an mRNA boost to strengthen the immune response. The goal is to see if this combination is safe and can produce broadly neutralizing antibodies against HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS [Site ID: 31788]
Birmingham, Alabama, 35294-2170, United States
-
BIDMC VCRS [Site ID: 32077]
Boston, Massachusetts, 02215, United States
-
Brigham & Women's Hospital [Site ID: 30007]
Boston, Massachusetts, 02115, United States
-
Emory University School of Medicine, The Ponce de Leon Center CRS [Site ID: 5802]
Atlanta, Georgia, 30303, United States
-
Seattle Vaccine and Prevention CRS [Site ID: 30331]
Seattle, Washington, 98104, United States
-
Vanderbilt Vaccine (VV) CRS [Site ID: 30352]
Nashville, Tennessee, 37232-2582, United States
Conditions
Explore the condition pages connected to this study.